^
    Back
    Association details:
    Biomarker:BRAF V600E + PIK3CA mutation
    Cancer:Astrocytoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Biol Ther
    Title:

    Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus

    Excerpt:
    We present a case of a patient who was firstly diagnosed with anaplastic oligoastrocytoma...Mutations of BRAF (V600E) and PIK3CA were reported by NGS. The patient benefited from the matched therapy vemurafenib and everolimus and got a long period of tumor control.
    DOI:
    10.1080/15384047.2018.1529115